Supernus Pharmaceuticals Files 8-K on Financial Condition

Ticker: SUPN · Form: 8-K · Filed: 2025-04-23T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations

Related Tickers: SUPN

TL;DR

SUPN filed an 8-K for Q1 2025 results, no major news.

AI Summary

On April 23, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition. The filing does not contain specific financial figures or significant events beyond the standard reporting requirement for the period ending April 23, 2025.

Why It Matters

This filing serves as a routine update on Supernus Pharmaceuticals' financial status, providing transparency to investors about the company's operational results.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting results of operations and financial condition without disclosing any new material events or significant financial changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Supernus Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition as of April 23, 2025.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is April 23, 2025.

In which state was Supernus Pharmaceuticals, Inc. incorporated?

Supernus Pharmaceuticals, Inc. was incorporated in Delaware.

What is the address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices?

The address of Supernus Pharmaceuticals, Inc.'s Principal Executive Offices is 9715 Key West Ave, Rockville, MD 20850.

Does this 8-K filing disclose any specific new financial results or material events?

Based on the provided text, this 8-K filing is a standard report on Results of Operations and Financial Condition and does not explicitly disclose specific new financial figures or material events beyond the reporting requirement itself.

From the Filing

0001356576-25-000020.txt : 20250423 0001356576-25-000020.hdr.sgml : 20250423 20250423172034 ACCESSION NUMBER: 0001356576-25-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250423 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20250423 DATE AS OF CHANGE: 20250423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 25862741 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 supn-20250423.htm 8-K supn-20250423 false 0001356576 0001356576 2025-02-11 2025-02-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 23, 2025   Supernus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35518 20-2590184 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 9715 Key West Ave Rockville MD 20850 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: ( 301 ) 838-2500   Not Applicable (Former name or former address, if changed since last report.)   Securities registered pursuant to Section 12(b) of the Exchange Act Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On April 23, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. The Company will host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. E.T. to discuss its first quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated April 23 , 2025 filed a

View on Read The Filing